Comparative study of transvaginal ultrasonography and CA 125 in the preoperative evaluation of myometrial invasion in endometrial carcinoma

e15564 Background: Preoperative evaluation of the risk for metastases in endometrial carcinoma is challenging. The aim of this study was to compare preoperative serum levels of angiogenetic markers VEGF, sFLT-1, and CD105 (endoglin) in predicting a metastasized disease. Methods: Preoperative sera from 100 consecutive patients diagnosed for endometrial carcinoma were collected. The serum concentrations of VEGF, sFLT-1, and CD105 were assessed by enzyme-linked immunosorbent assay (ELISA). The results were correlated to the presence of metastases, presence of deep (≥50%) myometrial invasion and histologic grade of the tumor. Cases with other than endometrioid histology were excluded from the study. Results: Eleven patients had a metastasized disease (≥Stage IIIA, FIGO 2009 classification). The serum concentration of VEGF was higher in the group with metastases (median [range] 394 pg/mL [31-1524 pg/mL] vs. 801 pg/mL [631-1183 pg/mL], p=0.001). The concentrations of sFLT-1 and CD105 did not show statistical difference between the two groups. In the multivariable analysis, the concentration of VEGF was the sole independent factor for the presence of metastases (OR 1.003, 95% CI 1.000-1.005, p=0.019). Conclusions: Preoperative serum VEGF concentration correlates with the presence of metastases in endometrioid endometrial carcinoma.

Download Full-text

PTEN protein expression has role in predicting disease-free-interval in endometrioid endometrial carcinoma

Hormone Molecular Biology and Clinical Investigation ◽

10.1515/hmbci-2021-0017 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Mohamad Nasir Shafiee ◽

Wei Keith Lim ◽

Cheryl Poh Shwen Shi ◽

Ira Adila Mohamed Yasin ◽

Aina Fatini Azemi ◽

...

Keyword(s):

Protein Expression ◽

Endometrial Carcinoma ◽

Myometrial Invasion ◽

Ca 125 ◽

Pten Protein ◽

Disease Free Interval ◽

Free Interval ◽

The Mean ◽

Endometrioid Endometrial Carcinoma ◽

Disease Free

Abstract Objectives To determine the significance of tumour PTEN protein expression in endometrioid endometrial carcinoma (EEC) and it is correlation with tumour characteristics. Methods A total of 30 eligible archived paraffin-embedded tissue blocks from 61 EEC cases (January 2015–December 2017) were retrieved from the Histopathology Laboratory in Universiti Kebangsaan Malaysia Medical Centre (UKMMC) following institutional ethic approval. For PTEN protein detection, immunohistochemistry (IHC) staining was performed and the data was correlated with clinicopathologic parameters. Results Fourteen samples (46.7%) showed positive PTEN protein expression, while 16 (53.3%) were negative. The mean age was 62.00 ± 9.51 years old, while the mean Body Mass Index (BMI) was 27.28 ± 7.16 kg/m2. There was no significant difference between age (p=0.27, 95% CI: −10.98 to 3.21) and BMI (p=0.67, 95% CI: −4.30 to 6.58) with PTEN protein expression. There were significant correlation between PTEN protein expression with myometrial invasion (p=0.010), but not with lymphovascular space invasion (p=0.743), grade (p=0.532), stage (p=0.733) and CA-125 level (p=0.47). The higher stage correlates with the presence of LVSI (p=0.002). PTEN positive associated with longer disease-free-interval (p=0.025), but not improving the overall survival (p=0.38) Conclusions Positive PTEN protein expression correlates with less myometrial invasion.

Download Full-text

Preoperative Evaluation Of Serum CA-125 Levels Maybe A More Significantly Prognostic Factor In Low To Intermediate-risk Endometrial Carcinoma: A Multi-institutional Study

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.06.1672 ◽

2019 ◽

Vol 105 (1) ◽

pp. E350-E351

Author(s):

X. Hou ◽

M. Shi ◽

L. Wei ◽

L. Zou ◽

T. Wang ◽

...

Keyword(s):

Prognostic Factor ◽

Endometrial Carcinoma ◽

Preoperative Evaluation ◽

Ca 125 ◽

Intermediate Risk

Download Full-text

Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma

American Journal of Obstetrics and Gynecology ◽

10.1016/0002-9378(90)90692-z ◽

1990 ◽

Vol 163 (4) ◽

pp. 1204-1209 ◽

Cited By ~ 34

Author(s):

John T. Soper ◽

Andrew Berchuck ◽

George J. Olt ◽

Andrew P. Soisson ◽

Daniel L. Clarke-Pearson ◽

...

Keyword(s):

Endometrial Carcinoma ◽

Preoperative Evaluation ◽

Ca 125

Download Full-text

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis

Diagnostic Pathology ◽

10.1186/s13000-021-01093-4 ◽

2021 ◽

Vol 16 (1) ◽

Author(s):

Soichiro Kakimoto ◽

Morikazu Miyamoto ◽

Takahiro Einama ◽

Yasuhiro Takihata ◽

Hiroko Matsuura ◽

...

Keyword(s):

Endometrial Carcinoma ◽

Lymphovascular Invasion ◽

Unmet Need ◽

Myometrial Invasion ◽

Progression Free Survival ◽

Ca 125 ◽

Tumor Aggressiveness ◽

Free Survival ◽

Clinicopathologic Factors ◽

Mesothelin Expression

Abstract Background This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma. Methods Between 1989 and 2017, patients with endometrial carcinoma who underwent total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either or both immunochemical expression of mesothelin and CA125 and clinicopathological features were retrospectively examined. Results Among 485 patients, 171 were positive for mesothelin, 368 were positive for CA125, and 167 were positive for mesothelin and CA125. The expression of mesothelin and CA125 was positively correlated (p < 0.01). More patients with mesothelin expression showed myometrial invasion of more than 50% (p = 0.028) and positive lymphovascular invasion (p = 0.027). Similarly, more patients with co-expression of mesothelin and CA125 had myometrial invasion of more than 50% (p = 0.016) and positive lymphovascular invasion (p = 0.02). Patients with mesothelin expression and co-expression of mesothelin and CA125 demonstrated worse progression-free survival (PFS) and overall survival (OS). In the multivariate analysis, mesothelin expression and co-expression were poor prognostic factors for PFS (mesothelin expression: hazard ratio [HR] = 2.14, p < 0.01; co-expression: HR = 2.19, p < 0.01) and OS (mesothelin expression: HR = 2.18, p < 0.01; co-expression: HR = 2.22, p < 0.01). Conclusions Mesothelin expression and co-expression might be associated with tumor aggressiveness and poor prognosis in patients with endometrial carcinoma. Persons with mesothelin-expressing endometrial cancers present a particularly high medical unmet need.

Download Full-text